About: Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers. It has a license agreement with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., Knight Therapeutics Inc., Specialised Therapeutics Asia Pte. Ltd., and Temple University. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Latest price: $0.34 (-6.60%)
TRAW NASDAQ Traws Pharma Inc
Traws Pharma Inc share price
TRAW price activity
Last Price
$0.340
Change (24hr)
-0.02 USD (6.60%)
Volume
105.15K
Volume (4w avg)
-
Open
$0.35
Day Range
$0.33 - $0.35
Previous Close
$0.37
Last Trade
23 Oct, 8:00 pm GMT+0
Delayed
23 Oct, 8:00 pm GMT+0
TRAW price performance
Delayed
23 Oct, 8:00 pm GMT+0
TRAW Market Signals